NCT00454337View on ClinicalTrials.gov

Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

PHASE3CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

HIV Infections

Interventions

DRUG

FTC/TDF + EFV or LPV/R +T20

emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day

DRUG

FTC/TDF + EFV or LPV/R

emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)

Trial Locations (1)

75010

Service des maladies infectieuses et tropicales Hopital Saint Louis, Paris

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00454337 - Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load | Biotech Hunter | Biotech Hunter